New Accutane Safety Measures May Come Soon

December 9, 2000 - 0:0
WASHINGTON Two months after Stacy Baumann's teenage son, Daniel, committed suicide, she wondered whether his acne medication could have provoked his death.
She went on-line and typed the words "Accutane" and "suicide." The Internet search turned up a two-year-old warning from U.S.
health officials that prescription Accutane, made by Swiss drug maker Roche Holding AG, may be associated with depression and suicide, although the link has never been proven.
"I just couldn't believe what I was learning for the very first time," Baumann told the House Government Reform Committee on Tuesday as she tearfully recounted her son's December 1999 death.
Baumann and other parents, plus members of Congress, said federal regulators, physicians, pharmacists and the drug maker need to better publicize the questions surrounding Accutane.
That may soon happen. A Food and Drug Administration (FDA) official told the committee that the agency and Roche were working out final details on providing all Accutane patients with a consumer-friendly pamphlet detailing possible risks.
The pamphlet, called a medication guide, could be available next month along with a new consent form that mentions possible psychiatric side effects, said Dr. Jonca Bull, deputy director of the FDA office that monitors Accutane.
Accutane, considered highly effective for the most disfiguring type of acne, already is closely watched because of it can cause severe birth defects.
The FDA is considering limiting prescribing practices to physicians who join a registry and promise to take steps to help women on Accutane avoid pregnancy.
The registry, which has drawn opposition from dermatologists, could be set up as early as next summer, Bull said.
One dermatologist told the committee that such tight controls could limit availability of the drug.
But he also acknowledged that while he counsels patients about possible psychiatric side effects, others do not.
"Many of my colleagues appear to be less informed than they should be," said Dr. David Pariser, speaking on behalf of the American Academy of Dermatology.
Accutane's possible psychiatric side effects received publicity in October, when Rep. Bart Stupak, a Michigan Democrat, said his son committed suicide while taking Accutane. Stupak did not testify at the hearing.
Studies have not been able to conclude whether Accutane could be linked to reports of depression and suicide.
Roche noted in a statement that both are relatively high among teenagers, especially those with disfiguring acne. The company said it continues to study the drug and is cooperating with the FDA.
"Roche is committed to ensuring that information relevant to the Accutane-treated patient population is carefully studied and properly communicated," the statement said.
(Reuter)